中国医药
中國醫藥
중국의약
CHINA MEDICINE
2010年
10期
896-897
,共2页
慢性乙型肝炎%干扰素%复方甘草酸苷
慢性乙型肝炎%榦擾素%複方甘草痠苷
만성을형간염%간우소%복방감초산감
Chronic hepatitis B%Interferon%Compound glycyrrhizin
目的 评价复方甘草酸苷与干扰α-2b联合治疗慢性乙型肝炎的临床疗效.方法 将76例慢性乙型肝炎患者完全随机分为治疗组(39例)和对照组(37例).治疗组由复方甘草酸苷和干扰素α-2b联合治疗;对照组为单用干扰素α-2b.对比2组患者临床各指标恢复情况.结果 与对照组比较,治疗组在治疗结束时的HBsAg转阴率、HBeAg转阴率、HBeAb转阳率和HBV-DNA转阴率各指标均明显高于对照组[7.7%比2.7%,64.1%比40.5%,53.8%比29.7%,71.8%比48.6%,P＜0.05或P＜0.01];随访6个月后,ALT复常率、HBeAg转阴率、HBeAb转阳率和HBV-DNA转阴率均明显高于对照组(P＜0.05或P＜0.01).结论 复方甘草酸苷与干扰素α-2b联合治疗慢性乙型肝炎的临床疗效明显优于单用干扰素α-2b.
目的 評價複方甘草痠苷與榦擾α-2b聯閤治療慢性乙型肝炎的臨床療效.方法 將76例慢性乙型肝炎患者完全隨機分為治療組(39例)和對照組(37例).治療組由複方甘草痠苷和榦擾素α-2b聯閤治療;對照組為單用榦擾素α-2b.對比2組患者臨床各指標恢複情況.結果 與對照組比較,治療組在治療結束時的HBsAg轉陰率、HBeAg轉陰率、HBeAb轉暘率和HBV-DNA轉陰率各指標均明顯高于對照組[7.7%比2.7%,64.1%比40.5%,53.8%比29.7%,71.8%比48.6%,P＜0.05或P＜0.01];隨訪6箇月後,ALT複常率、HBeAg轉陰率、HBeAb轉暘率和HBV-DNA轉陰率均明顯高于對照組(P＜0.05或P＜0.01).結論 複方甘草痠苷與榦擾素α-2b聯閤治療慢性乙型肝炎的臨床療效明顯優于單用榦擾素α-2b.
목적 평개복방감초산감여간우α-2b연합치료만성을형간염적림상료효.방법 장76례만성을형간염환자완전수궤분위치료조(39례)화대조조(37례).치료조유복방감초산감화간우소α-2b연합치료;대조조위단용간우소α-2b.대비2조환자림상각지표회복정황.결과 여대조조비교,치료조재치료결속시적HBsAg전음솔、HBeAg전음솔、HBeAb전양솔화HBV-DNA전음솔각지표균명현고우대조조[7.7%비2.7%,64.1%비40.5%,53.8%비29.7%,71.8%비48.6%,P＜0.05혹P＜0.01];수방6개월후,ALT복상솔、HBeAg전음솔、HBeAb전양솔화HBV-DNA전음솔균명현고우대조조(P＜0.05혹P＜0.01).결론 복방감초산감여간우소α-2b연합치료만성을형간염적림상료효명현우우단용간우소α-2b.
Objective To investigate the clinical effect of compound glycyrrhizin combined with interferon α-2b on chronic hepatitis B (CHB). Methods Seventy-six CHB patients were randomly assigned into treatment group (39 cases) and control group (37 cases). Treatment group were given compound glycyrrhizin (100 ml, 80 ml and 60 ml for 4 weeks respectively) combined with interferonα-2b (once a day for 4 weeks, and then 500 MU interferon a every day for 32 weeks) and control group were given the same dose of interferonα-2b. All patients were treated for 36 weeks and then were followed up for 24 weeks. Results By the end of therapeutic course, the rates of negative conversion of HBsAg, HBeAg, HBV-DNA and the rates of positive conversion of HbeAb in the experimental group were much higher those in control. By the end of follow-up, the ALT recovery rates, the rates of negative conversion of HBeAg and HBV-DNA and the rates of positive conversion of HbeAb in the experimental group have statistically higher than those in control. Conclusion The efficacy of compound glycyrrhizin combined with interferon α-2b treatment for CHB patients is high.
